Revenue Estimates Analysis of SAP SE(NYSE:SAP) and Rigel Pharmaceuticals, Inc.(NASDAQ:RIGL)

0
5

SAP SE (SAP) will report its next earnings on Jan 29 BMO. The company reported the earnings of $1.31/Share in the last quarter where the estimated EPS by analysts was $1.25/share. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 4.8%.

Many analysts are providing their Estimated Earnings analysis for SAP SE and for the current quarter 13 analysts have projected that the stock could give an Average Earnings estimate of $1.78/share. These analysts have also projected a Low Estimate of $1.7/share and a High Estimate of $1.83/share.

In case of Revenue Estimates, 13 analysts have provided their consensus Average Revenue Estimates for SAP SE as 8.3 Billion. According to these analysts, the Low Revenue Estimate for SAP SE is 8.16 Billion and the High Revenue Estimate is 8.46 Billion. The company had Year Ago Sales of 7.8 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for SAP to be -14.4%. They are projecting Next Quarter growth of 14.44%. For the next 5 years, SAP SE is expecting Growth of 9.75% per annum, whereas in the past 5 years the growth was 0.4% per annum.

Some buy side analysts are also providing their Analysis on SAP SE, where 5 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 2 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for SAP SE might touch $145 high while the Average Price Target and Low price Target is $128 and $105 respectively.

SAP SE closed its last trading session at $102.65 with the gain of 0.67%. The Market Capitalization of the company stands at 128.23 Billion. The Company has 52-week high of $127.16 and 52-week low of $94.81. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 3.68% where SMA50 and SMA200 are 0.86% and -7.8% respectively. The Company Touched its 52-Week High on 09/26/18 and 52-Week Low on 12/26/18.

The Relative Volume of the company is 0.68 and Average Volume (3 months) is 983.13 million. The company’s P/E (price to earnings) ratio is 26.96 and Forward P/E ratio of 18.57.

The company shows its Return on Assets (ROA) value of 9.5%. The Return on Equity (ROE) value stands at 16.3%. While it’s Return on Investment (ROI) value is 11%.

While looking at the Stock’s Performance, SAP SE currently shows a Weekly Performance of 8.25%, where Monthly Performance is 1.41%, Quarterly performance is -13.44%, 6 Months performance is -12.29% and yearly performance percentage is -9.48%. Year to Date performance value (YTD perf) value is 3.81%. The Stock currently has a Weekly Volatility of 1.40% and Monthly Volatility of 1.81%.

Rigel Pharmaceuticals, Inc. (RIGL) will report its next earnings on Feb 05 AMC. The company reported the earnings of $-0.14/Share in the last quarter where the estimated EPS by analysts was $-0.15/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 6.7%.

Many analysts are providing their Estimated Earnings analysis for Rigel Pharmaceuticals, Inc. and for the current quarter 7 analysts have projected that the stock could give an Average Earnings estimate of $0.01/share. These analysts have also projected a Low Estimate of $-0.14/share and a High Estimate of $0.04/share.

These analysts also forecasted Growth Estimates for the Current Quarter for RIGL to be 116.7%. They are projecting Next Quarter growth of 11.76%. For the next 5 years, Rigel Pharmaceuticals, Inc. is expecting Growth of -23.72% per annum, whereas in the past 5 years the growth was 30.65% per annum.

Some buy side analysts are also providing their Analysis on Rigel Pharmaceuticals, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Rigel Pharmaceuticals, Inc. might touch $10 high while the Average Price Target and Low price Target is $8.07 and $7 respectively.

Rigel Pharmaceuticals, Inc. closed its last trading session at $2.39 with the loss of -3.77%. The Market Capitalization of the company stands at 383.29 Million. The Company has 52-week high of $4.71 and 52-week low of $1.96. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -5.27% where SMA50 and SMA200 are -13.73% and -26.23% respectively. The Company Touched its 52-Week High on 01/23/18 and 52-Week Low on 12/26/18.

The Relative Volume of the company is 1.34 and Average Volume (3 months) is 2.2 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -82.6%. The Return on Equity (ROE) value stands at -97.7%. While it’s Return on Investment (ROI) value is -79.1%.

While looking at the Stock’s Performance, Rigel Pharmaceuticals, Inc. currently shows a Weekly Performance of 5.99%, where Monthly Performance is -16.36%, Quarterly performance is -27.22%, 6 Months performance is -20.96% and yearly performance percentage is -42.79%. Year to Date performance value (YTD perf) value is 0%. The Stock currently has a Weekly Volatility of 7.08% and Monthly Volatility of 7.35%.

SHARE